Targeted Protein Degrader (TPD) biomarker services

Targeted protein degraders (TPDs) offer great promise in treating some of the most challenging diseases thanks to their ability to degrade ‘undruggable’ disease-associated proteins.

Consequently, the field has grown rapidly and continues to evolve at pace.

But developing a TPD isn’t easy. For success, developers must:

• Confidently grasp their TPD’s mechanism of action and accurately monitor target protein degradation to assess potency and optimize dosing schedules
• Unravel the complex causes of any TPD resistance that occurs so they can quickly overcome it

Without the right biomarker capabilities to overcome these challenges, TPD development can become more costly and convoluted than necessary.

With significant scientific expertise and custom assay design experience, CellCarta can steer you through the complexities of understanding TPD potency, dose adaptation, and resistance mechanisms, helping you increase your chances of TPD clinical development success.

By partnering with us, you get:

• Expert-driven clinical guidance, combined with a comprehensive multi-omic approach and sample logistics support, to help tackle the toughest biomarker challenges in clinical development
• A breadth of complementary tools covering immune monitoring, genomics, proteomics, and histology
• The ability to generate specific and quantitative data to help accurately assess potency and optimize dosing schedules
• A way to confidently elucidate the causes of patient resistance

As a global CRO with targeted protein degradation expertise, we align to the highest quality standards, with CAP accreditations, CLIA certifications, and validation processes that meet the requirements for primary and secondary endpoints

We offer a multi-omic approach and a wealth of expertise to help you better understand your TPD’s potency to refine dosing and scheduling.

• Accurately measure target protein degradation kinetics, depth, and recovery, and evaluate drug specificity in liquid biopsies and tissues using mass spectrometry 
• Track target protein degradation and explore drug specificity in cell sub-populations using flow cytometry
• Gain spatial target protein degradation information with IHC/IF assays

These assays are aligned with regulatory expectations and enable translational insights for TPD programs.

We can help you better stratify and monitor patients, as well as unravel mechanisms of TPD resistance to maximize your chance of clinical trial success.

Take advantage of:

• Advanced sequencing tools, histology assays, and companion diagnostic (CDx) know-how  to ensure patients most likely to benefit from treatment are included in your trial
• Technologies to help you generate more comprehensive data about your TPD, and better understand and track patient responses — from non-invasive monitoring of circulating tumour cells to cytokine storm monitoring
• An array of approaches to help you decode complex TPD resistance pathways and monitor for their activation, including next-generation sequencing (TSO500) panel, whole exome sequencing, RNA sequencing and NanoString

This full suite of TPD testing tools supports biomarker-led trial

As a specialized CRO with TPD expertise, CellCarta combines 20+ years of biomarker assay development with global laboratory infrastructure to help sponsors confidently navigate complex TPD programs.

Our services include:

• Custom TPD biomarker strategies and assay validation
• PK and drug mechanism assays for targeted protein degraders
• Multi-omic data integration across mass spectrometry, IHC, and RNAseq
• Global logistics, CAP/CLIA compliance, and clinical endpoint support

Trusted by leading TPD developers worldwide, CellCarta ensures scientific precision, regulatory readiness, and support from preclinical to late-stage clinical studies.